Scleroderma. Chronic multisystemic disease characterized by vasculopathy, variable degree of inflammation, and fibrosis

Size: px
Start display at page:

Download "Scleroderma. Chronic multisystemic disease characterized by vasculopathy, variable degree of inflammation, and fibrosis"

Transcription

1 Scleroderma Chronic multisystemic disease characterized by vasculopathy, variable degree of inflammation, and fibrosis Incidence cases/million Female:male 5:1 Pulmonary fibrosis common, severe in 16%. Pulmonary hypertension occurs in 50% of cases and can lead to cor pulmonale. Pulmonary complications are the leading cause of death in this disease. Clinical Features of Scleroderma (Systemic sclerosis; SSc) Typical facial features in advanced SSc Digital ulceration from vascular damage 1

2 CREST: Calcinosis, Raynaud s phenomenon, Sclerodactyly, Esophageal dysmotility, Telangiectasias Telangiectasias Ranaud s phenomenon Calcinosis Sclerodactyly Organ Involvement in Scleroderma Differential organ involvement in SSc. The earliest pathological feature of SSc in the skin is vasculopathy with endothelial cell activation. Later, inflammation develops and finally fibrosis is prominent. Similar processes are likely to occur in all lesional tissues, leading to organ dysfunction. Cardiac, renal, lung and gut complications are the main causes of SSc-related mortality. From: Denton and Black Trends Immunol. 26:596,

3 Pulmonary Manifestations of Scleroderma Normal Pulmonary Pulmonary Hypertension Fibrosis Major Clinical Sub-types of Scleroderma Limited cutaneous SSc (60% of cases) No skin sclerosis proximal to knees or elbows. Longstanding Raynaud's phenomenon is typical. Most commonly associated autoantibody is anti-centromere Ab (ACA). A subgroup of these patients has manifestations of CREST (calcinosis, Raynaud's, esophageal dysmotility, telangiectasis). Isolated pulmonary hypertension and gastrointestinal tract dysmotility are the most common severe manifestations. Lung fibrosis, renal and cardiac involvement occur less often than in dcssc. 3

4 Major Clinical Sub-types of Scleroderma Diffuse cutaneous SSc (30% of cases) The cardinal feature is skin sclerosis proximal to the knees and elbows. Raynaud's phenomenon is universal but might manifest simultaneously or shortly after the development of skin sclerosis. Inflammatory features are prominent during the first 3 years of disease. Skin involvement often diminishes within two years. ACA is rarely present, anti-scl-70 (topoisomease-1) or anti-rna polymerase is typical. There is a high frequency of interstitial lung disease, renal crisis and cardiac involvement. Major Clinical Sub-types of Scleroderma Scleroderma overlap syndromes Their features include those of limited or diffuse cutaneous SSc, together with those of one or more additional autoimmune rheumatic diseases, such as polyarthritis, myositis or SLE. Often associated with anti U1-ribonucleoprotein (U1-RNP), U3-RNP or polymyositis-scleroderma (PM-Scl) autoantibody reactivity. Localized scleroderma Morphea scleroderma causes patches of hard skin that can persist for years. Linear scleroderma causes bands of hard skin across the face or an extremity, rarely involving muscle or bone Typically carries a good prognosis 4

5 Genetics of Scleroderma Family history associated with increased risk of developing disease, but risk is only 1% for any individual. Concordance for both mono- and dizygotic twins is 5%. However, gene expression profiling of cultured dermal fibroblasts from monozygotic twins of an index case show a similar pro-fibrotic signature 46% of the time. Genetic studies indicate an association of scleroderma with polymorphisms in the promoters of the TNF, MCP-1, and CD19 genes. Although genetic studies have suggested an association of the HLA- DRB1*01 allele with anti-centromere antibodies, association of ACA with polymorphisms in the TNF promoter was even stronger, suggesting linkage disequilibrium. The Role of B Cells in Scleroderma In the blood of patients with scleroderma, naive B cells are increased in number, while memory B cells and plasmablasts/early plasma cells are diminished. Memory B cells express higher levels of CD80 and CD86, and thus are chronically activated, possibly due to CD19 over-expression. CD95 expression is also increased on memory B cells, leading to augmented CD95-mediated apoptosis. The continuous loss of memory B cells and plasmablasts/early plasma cells may increase naive B-cell production in bone marrow to maintain the B-cell homeostasis in systemic sclerosis. From: Fujimoto and Sato: Curr. Opin. Rheumatol. 17:746,

6 The Role of B Cells in Scleroderma Legend From: Fujimoto and Sato: Curr. Opin. Rheumatol. 17:746, 2005 Do B Cells and Autoantibodies Play a Causative Role in Scleroderma? 6

7 Autoantibodies to the PDGF Receptor Stimulates Production of Reactive Oxidants Oxidant production triggered by sera-derived IgG upon incubation with fibroblasts over-expressing the PDGF receptor. N, normal controls; SSc, scleroderma; PRP, primary Raynaud s phenomenon ; SLE, systemic lupus erythematosis; RA, rheumatoid arthritis; ILD, interstitial lung disease; AG 1296, PDGFR kinase inhibitor. From: Baroni et al., New Engl. J. Med. 354:2667,

8 Scleroderma-derived Antibodies to the PDGF Receptor Stimulate Cell Signaling and Collagen Production IP: PDGF receptor Blot Legend: FCS, fetal calf serum; AG1478, EGFR tyrosine kinase inhibitor; AG1296, PDGFR kinase inhibitor Adapted from: Baroni et al., New Engl. J. Med. 354:2667, 2006 Auto-antibodies to the PDGF Receptor: The Pathogenesis of Scleroderma Revealed? Unlike normal fibroblasts, fibroblasts in scleroderma increase the expression of PDGFR in response to TGF-, rendering the cells more sensitive to PDGF. The Ras ERK1/2 ROS signaling pathway is triggered by PDGF or anti- PDGFR, which then activates NADPH oxidase (NOX1) to produce reactive oxygen species (ROS). These, in turn, activate extracellular signal-regulated kinases 1 and 2 (ERK1/2), which induce the H-ras gene. This signaling loop is present in normal fibroblasts but is relatively amplified in fibroblasts in patients with scleroderma. From: Tan, New Engl. J. Med. 354:2709,

9 Potential Therapeutics for Scleroderma Based on Insight Into its Pathogenesis From: Baroni et al., New Engl. J. Med. 354:2667, If chronic over-stimulation of the PDGFR is required for the development and/or progression of scleroderma, then inhibition of PDGFR kinase activity (AG 1296), Ras post-translational processing (FTI 277), or ERK MAP kinase (PD 98059) may prove therapeutic. Therapeutic Approach to the Treatment of Scleroderma From: Denton and Black Trends Immunol. 26:596,

10 Fibrosis Can Occur in Any Organ and Can Lead to Irreversible Organ Damage Various theories have been proposed for the pathogenesis of fibrosing diseases. One view is that fibrosis represents a pathological variant of wound healing. An alternate view is that fibrosis is due to unresolved inflammation. Another view is that fibrosis results from an imbalance in the activities of proteases and anti-proteases. Regardless of the precise etiology of fibrosis, the pathological deposition of collagen and other components of the extracellular matrix results from persistence of mesenchymal cells assuming a fibroblastic or myofibroblastic phenotype, producing copious amounts of components of the ECM. Examples of Fibrosis Normal glomerulus Hepatitis C cirrhosis Glomerulosclerosis Retroperioneal fibrosis 10

11 Idiopathic Pulmonary Fibrosis (IPF) Normal IPF From: Best et al., Radiology 228:407, 2003; Wittram et al. Radiographics 23:1057, Three questions worth pondering 1. What cells and molecules participate in fibrosis? 2. What is the pathogenesis of fibrosis? 3. Can we intervene therapeutically and retard or reverse fibrosis? 11

12 Fibrosis Results from the Inappropriate Deposition of Extracellular Matrix Collagen Fibronectin Laminin Proteoglycan Integrin Two Engaging Members of the ECM Fibronectin Laminin 12

13 Diversity in Cells and Component of the ECM Collagen Anchor Proteoglycan Cell-Surface Receptor Cells I fibronectin chondroitin and dermatan sulfates integrin fibroblasts II fibronectin chondroitin sulfate integrin chondrocytes III fibronectin quiescent hepatocytes, heparan sulfate and integrin epithelial; assoc. heparin fibroblasts IV laminin heparan sulfate and heparin laminin receptors all epithelial cells, endothelial cells, regenerating hepatocytes V fibronectin heparan sulfate and heparin integrin quiescent fibroblasts VI fibronectin heparan sulfate Iitegrin quiescent fibroblasts Do not memorize this list Fibrosis is triggered by growth factors, cytokines, and peptides 13

14 Important Pro-fibrotic Growth Factors Growth factors TGF-, PDGF, FGF-2 (basic FGF), IGF-I, Connective tissue growth factor (CTGF), EGF Cytokines Th2 cytokines (IL-4, IL-13); IL-1, IL-6 Peptides Endothelin I, Ang-II Chemokines C-C chemokines Do memorize this list Activation of Latent TGF- : Not So Simple TGF- is synthesized by virtually all types of cells, in the form of an inactive homodimeric propeptide, pro-tgf-. After TGF- is cleaved from the pro-peptide, additional downstream events control the extent to which TGF- is available. The small latent complex, composed of TGF- and its latency-associated peptide, and the large latent complex, composed of TGF-, latency-associated peptide, and the latent TGF- binding protein control where and when active TGF- is made available. The matrix protein thrombospondin-1 binds to the latencyassociated peptide, which results in the activation of TGF-, an essential step for the binding of TGF- to its receptors. Plasmin, some MMPs, and two members of the integrin family also activate the latent complexes of TGF-. From: Ugust and Suthanthiran New Engl. J. Med. 354: 2721,

15 Basic Paradigm of TGF- Signal Transduction Legend From: Yokote et al., Trends Cardiovasc. Med. 16:240, 2006 Anti-proliferative and Pro-fibrotic Properties of TGF- Signaling Revealed by Gene Targeting in Mice Enhanced neointimal hyperplasia and reduced matrix deposition in the arteries of Smad3-null mice upon injury. Photomicrographs showing representative cross sections of hematoxylin/eosin-stained (A and B) and Masson's trichrome-stained (C and D) femoral arteries from wild-type (A and C) and Smad3-null (B and D) mice 3 weeks after endothelial injury by photochemically induced thrombosis method. Arrows indicate the positions of the internal elastic lamina. L, vascular lumen. Frrom: Circ Res 96:904,

16 The Myofibroblast, a Collagen-producing Contractile Cell Involved in Wound Healing -smooth muscle actin The Hepatic Stellate Cell is the Myofibroblast-equivalent in Cirrhosis From Bataller and Brenner, J. Clin. Invest. 115:209,

17 What are the cellular origins of fibroblasts and myofibroblasts? Local proliferation of mesenchymal cells Influx of blood-borne fibroblast precursors (often termed fibrocytes ) Epithelial-mesenchymal transformation (EMT) Use of Bone Marrow Chimeras to Determine the Cellular Origin of Fibroblasts Representative lung sections from bleomycin (BLM)-treated (a c) or saline-treated (d f) GFP BM chimera mice were evaluated at day 28 after BLM or saline treatment. The H&E-stained sections revealed severe distortion of lung alveolar architecture due to extensive fibrosis (a and b, at x40 and x200, respectively). (c) Numerous GFP + cells in densely cellular fibrotic lesions were easily identifiable by fluorescence microscopy in BLM-treated lungs. x200. In contrast, H&E-stained lung sections from saline-treated GFP BM chimera mice showed normal lung architecture (d and e, at x40 and x200, respectively), with a few scattered GFP + cells visualized by fluorescence microscopy (f, at x200). Insets in c and f showed the light-microscopic appearance of the respective sections examined by fluorescence microscopy. x200. From: Hashimoto et al., J. Clin. Invest. 113:243,

18 GFP+ Col I+ Cells Derived from the Bone Marrow Populate Lungs During Experimental Pulmonary Fibrosis in Mice Representative flow cytometry tracings of cells isolated from lungs of bleomycin- and control saline-treated mice and stained with antibodies that detect Col I. Insets show staining of cells using an isotype-matched control antibody. From: Hashimoto et al., J. Clin. Invest. 113:243, Epithelial-mesenchymal Transformation (EMT) (a) Schematic of EMT. Epithelial cells (in blue) adhere to each other through adherens junctions, using E-cadherin (E-cad), and their desmosomes (tight junctions) constituted by various proteins such as desmoplakin (dp). Mesenchymal cells (in red) are neither adherent nor apically polarized and have low expression of E-cadherin and desmoplakin. The intermediate filament protein vimentin (vim) is induced in mesenchymal cells. (b g) EMT in a human squamous cell carcinoma line. Prior to EMT (b) and after EMT (c). E-cadherin (red in d and e) and vimentin (f and g) immunolocalization in epithelial (d and f) and mesenchymal cells following EMT (e and g). Adapted from Larue and Bellacosa, Oncogene 24:7443,

19 E-Cadherin Appears to be a Critical Regulator of EMT Is repression/disruption of E-cadherin expression sufficient to induce EMT? The Canonical Wnt Pathway Leads to Activation of a Subset of Genes Important in Development N.B.: Do not memorize 19

20 Repressing E-Cadherin Triggers EMT TGF- 2/3 Wnt P cytoplasm Smad2 Smad4 TCF TCF -cat nucleus e-cadherin promoter e-cadherin Twist Slug Snail N.B.: Do not memorize FGF, TGF-? IL-4, IL-13 Summary 1. Scleroderma is an autoimmune disease involving multiple organs. It is characterized by a vasculopathy, varying degrees of inflammation, and fibrosis. Several major clinical variants of scleroderma have been described. 2. Pulmonary complications of scleroderma are common and severe in substantial minority. Death is due to severe pulmonary hypertension, pulmonary fibrosis, or both, ultimately leading to cor pulmonale. 3. Autoantibodies play an important role in the pathogenesis to scleroderma. Agonistic autoantibodies against the PDGFR have been isolated from patients with scleroderma. 4. Various theories of fibrogenesis have been proposed. Regardless of the precise etiology, fibrosis is due to the excessive deposition of ECM by the major collagenproducing cells in the body, fibroblasts and myofibroblasts. 5. Fibroblasts arise from a combination of local proliferation of resident mesenchymal cells, EMT, and influx of fibroblast precursors from the bone marrow. 6. Among the various pro-fibrogenic growth factors, TGF- usually plays an important role in fibrosis. TGF- triggers increased production of ECM proteins, induces EMT, and typically induces proliferation (rather than cell cycle arrest) in fibroblasts. 20

Scleroderma. Nomenclature Synonyms. Scleroderma. Progressive Systemic Sclerosis. Systemic Sclerosis. Edward Dwyer, M.D. Division of Rheumatology

Scleroderma. Nomenclature Synonyms. Scleroderma. Progressive Systemic Sclerosis. Systemic Sclerosis. Edward Dwyer, M.D. Division of Rheumatology Scleroderma Edward Dwyer, M.D. Division of Rheumatology Nomenclature Synonyms Scleroderma Progressive Systemic Sclerosis Systemic Sclerosis Scleroderma 1 Scleroderma Chronic systemic autoimmune disease

More information

Scleroderma. Nomenclature Synonyms. Scleroderma. Progressive Systemic Sclerosis. Systemic Sclerosis. Limited vs. Diffuse Scleroderma.

Scleroderma. Nomenclature Synonyms. Scleroderma. Progressive Systemic Sclerosis. Systemic Sclerosis. Limited vs. Diffuse Scleroderma. Scleroderma Edward Dwyer, M.D. Division of Rheumatology Nomenclature Synonyms Scleroderma Progressive Systemic Sclerosis Systemic Sclerosis Scleroderma Chronic systemic autoimmune disease characterized

More information

SCLERODERMA 101. Maureen D. Mayes, MD, MPH Professor of Medicine University of Texas - Houston

SCLERODERMA 101. Maureen D. Mayes, MD, MPH Professor of Medicine University of Texas - Houston SCLERODERMA 101 Maureen D. Mayes, MD, MPH Professor of Medicine University of Texas - Houston TYPES OF SCLERODERMA Localized versus Systemic Two Kinds of Scleroderma Localized Scleroderma Morphea Linear

More information

European Respiratory Society Annual Congress. Presented at: of new drugs for respiratory diseases. Barcelona, Spain, September 7-11, 2013 Page 1

European Respiratory Society Annual Congress. Presented at: of new drugs for respiratory diseases. Barcelona, Spain, September 7-11, 2013 Page 1 PBI-4050, a novel first-in-class anti-fibrotic compound, reduces lung fibrosis in the bleomycin-induced lung fibrosis model: a comparative study with pirfenidone Presented at: Thematic Poster Session:

More information

Tissue repair. (3&4 of 4)

Tissue repair. (3&4 of 4) Tissue repair (3&4 of 4) What will we discuss today: Regeneration in tissue repair Scar formation Cutaneous wound healing Pathologic aspects of repair Regeneration in tissue repair Labile tissues rapid

More information

Test Name Results Units Bio. Ref. Interval

Test Name Results Units Bio. Ref. Interval LL - LL-ROHINI (NATIONAL REFERENCE 135091593 Age 25 Years Gender Male 30/8/2017 91600AM 30/8/2017 93946AM 31/8/2017 84826AM Ref By Final COLLAGEN DISEASES ANTIBODY ANEL ANTI NUCLEAR ANTIBODY / FACTOR (ANA/ANF),

More information

Abnormally differentiating keratinocytes in the epidermis of systemic sclerosis patients show enhanced secretion of CCN2 and S100A9

Abnormally differentiating keratinocytes in the epidermis of systemic sclerosis patients show enhanced secretion of CCN2 and S100A9 Abnormally differentiating keratinocytes in the epidermis of systemic sclerosis patients show enhanced secretion of CCN2 and S1A9 Joanna Nikitorowicz-Buniak UCL Division of Medicine Systemic sclerosis

More information

vi Preface Table 2 Association of Fibrosis With Types of Injury: Representative Examples

vi Preface Table 2 Association of Fibrosis With Types of Injury: Representative Examples Fibrosis or scar, defined pathologically as inappropriate repair by connective tissue, is increasingly recognized as an important feature of many chronic diseases (Table 1), and as such, represents an

More information

Uncovering the mechanisms of wound healing and fibrosis

Uncovering the mechanisms of wound healing and fibrosis Any Questions??? Ask now or contact support support@sabiosciences.com 1-888-503-3187 International customers: SABio@Qiagen.com Uncovering the mechanisms of wound healing and fibrosis Webinar related questions:

More information

Test Name Results Units Bio. Ref. Interval

Test Name Results Units Bio. Ref. Interval 135091660 Age 44 Years Gender Male 29/8/2017 120000AM 29/8/2017 100219AM 29/8/2017 105510AM Ref By Final EXTRACTABLENUCLEAR ANTIGENS (ENA), QUANTITATIVE ROFILE CENTROMERE ANTIBODY, SERUM 20-30 Weak ositive

More information

Laura Smart 9/22/2011

Laura Smart 9/22/2011 Laura Smart 9/22/2011 Fibrosis is a wound healing response in which damaged regions are encapsulated by an extracellular matrix or scar. Fibrosis develops in almost all patients with chronic liver injury

More information

Test Name Results Units Bio. Ref. Interval

Test Name Results Units Bio. Ref. Interval 135091662 Age 45 Years Gender Male 29/8/2017 120000AM 29/8/2017 100215AM 29/8/2017 110825AM Ref By Final RHEUMATOID AUTOIMMUNE COMREHENSIVE ANEL ANTI NUCLEAR ANTIBODY / FACTOR (ANA/ANF), SERUM ----- 20-60

More information

Clinical Laboratory. [None

Clinical Laboratory. [None Clinical Laboratory Procedure Result Units Ref Interval Accession Collected Received Double-Stranded DNA (dsdna) Ab IgG ELISA Detected * [None 18-289-900151 Detected] Double-Stranded DNA (dsdna) Ab IgG

More information

Immunological Lung Diseases

Immunological Lung Diseases Emphysema and Fibrosis Universitätsklinik für Pneumologie Prof. Thomas Geiser Head Div. of Pulmonary Medicine and Laboratory of Lung Research, MU50 thomas.geiser@insel.ch The healthy lung: The pathway

More information

Understanding Root Cause: Pathogenesis of Hepatic Fibrosis

Understanding Root Cause: Pathogenesis of Hepatic Fibrosis 10/1/12 Understanding Root Cause: Pathogenesis of Hepatic Fibrosis Hepatitis C Virus Mild inflammation Inflammation Fibrosis Cirrhosis 1 10/1/12 Non-alcoholic Fatty Liver Disease Steatosis Steatohepatitis

More information

SCLERODERMA. Scleroderma update. No disclosures or conflicts. Leslie Kahl, M.D. April 10, 2015

SCLERODERMA. Scleroderma update. No disclosures or conflicts. Leslie Kahl, M.D. April 10, 2015 Scleroderma update Leslie Kahl, M.D. April 10, 2015 No disclosures or conflicts KT is a 45 year old woman who developed puffiness in her fingers 1/2013 and carpal tunnel syndrome and arthralgias 3/2013.

More information

Mechanisms of hepatic fibrogenesis in chronic liver disease

Mechanisms of hepatic fibrogenesis in chronic liver disease Mechanisms of hepatic fibrogenesis in chronic liver disease JPEMS 2014, Physiopathology Module Corentin Bessy (Nantes) _ Gabrielle Cepella (Amsterdam) _ Charly Gaisne (Angers) _ Gwladys Guilloineau (Angers)

More information

Healing & Repair. Tissue Regeneration

Healing & Repair. Tissue Regeneration Healing & Repair Dr. Srikumar Chakravarthi Repair & Healing: Are they same? Repair :Regeneration of injured cells by cells of same type, as with regeneration of skin/oral mucosa (requires basement membrane)

More information

1.The metastatic cascade. 2.Pathologic features of metastasis. 3.Therapeutic ramifications

1.The metastatic cascade. 2.Pathologic features of metastasis. 3.Therapeutic ramifications Metastasis 1.The metastatic cascade 2.Pathologic features of metastasis 3.Therapeutic ramifications Sir James Paget (1814-1899) British Surgeon/ Pathologist Paget s disease of bone Paget s disease of the

More information

Small Molecule Inhibitor of the Wnt Pathway (SM04755) as a Potential Topical Scleroderma Treatment

Small Molecule Inhibitor of the Wnt Pathway (SM04755) as a Potential Topical Scleroderma Treatment Small Molecule Inhibitor of the Wnt Pathway (SM755) as a Potential Topical Scleroderma Treatment Vishal Deshmukh, PhD, Allison Hood, Yusuf Yazici, MD Disclosures Vishal Deshmukh, Ph.D. o Financial disclosure:

More information

Update in Systemic Sclerosis! Lauren Kim MD! NW Rheumatology Associates

Update in Systemic Sclerosis! Lauren Kim MD! NW Rheumatology Associates Update in Systemic Sclerosis! Lauren Kim MD! NW Rheumatology Associates Review Systemic sclerosis affects approximately 75,000 to 100,000 people in the U.S. and has the highest mortality rate of any autoimmune

More information

Clinical Laboratory. 14:42:00 SSA-52 (Ro52) (ENA) Antibody, IgG 1 AU/mL [0-40] Oct-18

Clinical Laboratory. 14:42:00 SSA-52 (Ro52) (ENA) Antibody, IgG 1 AU/mL [0-40] Oct-18 Clinical Laboratory Procedure Result Units Ref Interval Accession Collected Received Rheumatoid Factor

More information

Cell Cell Communication

Cell Cell Communication IBS 8102 Cell, Molecular, and Developmental Biology Cell Cell Communication January 29, 2008 Communicate What? Why do cells communicate? To govern or modify each other for the benefit of the organism differentiate

More information

Supplemental Table 1. Primer sequences for transcript analysis

Supplemental Table 1. Primer sequences for transcript analysis Supplemental Table 1. Primer sequences for transcript analysis Primer Sequence (5 3 ) Primer Sequence (5 3 ) Mmp2 Forward CCCGTGTGGCCCTC Mmp15 Forward CGGGGCTGGCT Reverse GCTCTCCCGGTTTC Reverse CCTGGTGTGCCTGCTC

More information

Healing and Repair. Dr. Nabila Hamdi MD, PhD

Healing and Repair. Dr. Nabila Hamdi MD, PhD Healing and Repair Dr. Nabila Hamdi MD, PhD 1 ILOs Know the classification of human cells according to their ability for proliferation. Understand the mechanism of cellular regeneration. Identify the types

More information

Tissue renewal and Repair. Nisamanee Charoenchon, PhD Department of Pathobiology, Faculty of Science

Tissue renewal and Repair. Nisamanee Charoenchon, PhD   Department of Pathobiology, Faculty of Science Tissue renewal and Repair Nisamanee Charoenchon, PhD Email: nisamanee.cha@mahidol.ac.th Department of Pathobiology, Faculty of Science Topic Objectives 1. Describe processes of tissue repair, regeneration

More information

Cell Cell Communication

Cell Cell Communication IBS 8102 Cell, Molecular, and Developmental Biology Cell Cell Communication January 29, 2008 Communicate What? Why do cells communicate? To govern or modify each other for the benefit of the organism differentiate

More information

9/15/11. Dr. Vivien Hsu Director, UMDNJ Scleroderma Program New Brunswick, NJ September Scleroderma. Hard skin

9/15/11. Dr. Vivien Hsu Director, UMDNJ Scleroderma Program New Brunswick, NJ September Scleroderma. Hard skin Dr. Vivien Hsu Director, UMDNJ Scleroderma Program New Brunswick, NJ September 2011 Scleroderma Hard skin 1 No diagnostic test for scleroderma Pathogenesis is unknown prominent features of disease reflect

More information

1. The metastatic cascade. 3. Pathologic features of metastasis. 4. Therapeutic ramifications. Which malignant cells will metastasize?

1. The metastatic cascade. 3. Pathologic features of metastasis. 4. Therapeutic ramifications. Which malignant cells will metastasize? 1. The metastatic cascade 3. Pathologic features of metastasis 4. Therapeutic ramifications Sir James Paget (1814-1899) British Surgeon/ Pathologist Paget s disease of Paget s disease of the nipple (intraductal

More information

In vitro scratch assay: method for analysis of cell migration in vitro labeled fluorodeoxyglucose (FDG)

In vitro scratch assay: method for analysis of cell migration in vitro labeled fluorodeoxyglucose (FDG) In vitro scratch assay: method for analysis of cell migration in vitro labeled fluorodeoxyglucose (FDG) 1 Dr Saeb Aliwaini 13/11/2015 Migration in vivo Primary tumors are responsible for only about 10%

More information

Autoimmune diseases. SLIDE 3: Introduction to autoimmune diseases Chronic

Autoimmune diseases. SLIDE 3: Introduction to autoimmune diseases Chronic SLIDE 3: Introduction to autoimmune diseases Chronic Autoimmune diseases Sometimes relapsing : and remitting. which means that they present as attacks Progressive damage Epitope spreading more and more

More information

Role of Inflammation in Pulmonary Hypertension

Role of Inflammation in Pulmonary Hypertension Role of Inflammation in Pulmonary Hypertension K. R. Stenmark University of Colorado Denver, USA Prominent Fibroproliferative Changes are Observed in the Lung Vasculature of Infants With Pulmonary Arterial

More information

Src-INACTIVE / Src-INACTIVE

Src-INACTIVE / Src-INACTIVE Biology 169 -- Exam 1 February 2003 Answer each question, noting carefully the instructions for each. Repeat- Read the instructions for each question before answering!!! Be as specific as possible in each

More information

Pursuing Novel Pathways in Immunology: Merck Presents New Clinical Data at 2017 ACR/ARHP Annual Meeting

Pursuing Novel Pathways in Immunology: Merck Presents New Clinical Data at 2017 ACR/ARHP Annual Meeting Your Contact Brenda Mulligan +1 (978) 821-5345 October 20, 2017 ACR Abstract # Atacicept: 889, 2585, 2586, 2610; Sprifermin: 1207, 2183, 1L; Abituzumab: 774; Evobrutinib: 2565; Discovery Products: 25,

More information

Rheumatoid Arthritis. Manish Relan, MD FACP RhMSUS Arthritis & Rheumatology Care Center. Jacksonville, FL (904)

Rheumatoid Arthritis. Manish Relan, MD FACP RhMSUS Arthritis & Rheumatology Care Center. Jacksonville, FL (904) Rheumatoid Arthritis Manish Relan, MD FACP RhMSUS Arthritis & Rheumatology Care Center. Jacksonville, FL (904) 503-6999. 1 Disclosures Speaker Bureau: Abbvie 2 Objectives Better understand the pathophysiology

More information

Budsakorn Darawankul, MD. Maharat Nakhon Ratchasima Hospital

Budsakorn Darawankul, MD. Maharat Nakhon Ratchasima Hospital Budsakorn Darawankul, MD. Maharat Nakhon Ratchasima Hospital Outline What is ANA? How to detect ANA? Clinical application Common autoantibody in ANA diseases Outline What is ANA? How to detect ANA? Clinical

More information

Pursuing Novel Pathways in Immunology: Merck KGaA, Darmstadt, Germany Presents New Clinical Data at 2017 ACR/ARHP Annual Meeting

Pursuing Novel Pathways in Immunology: Merck KGaA, Darmstadt, Germany Presents New Clinical Data at 2017 ACR/ARHP Annual Meeting News Release Your Contact Brenda Mulligan +1 (978) 821-5345 October 20, 2017 ACR Abstract # Atacicept: 889, 2585, 2586, 2610; Sprifermin: 1207, 2183, 1L; Abituzumab: 774; Evobrutinib: 2565; Discovery Products:

More information

CELL BIOLOGY - CLUTCH CH CELL JUNCTIONS AND TISSUES.

CELL BIOLOGY - CLUTCH CH CELL JUNCTIONS AND TISSUES. !! www.clutchprep.com CONCEPT: CELL-CELL ADHESION Cells must be able to bind and interact with nearby cells in order to have functional and strong tissues Cells can in two main ways - Homophilic interactions

More information

Clinical Laboratory. 14:41:00 Complement Component 3 50 mg/dl Oct-18

Clinical Laboratory. 14:41:00 Complement Component 3 50 mg/dl Oct-18 Clinical Laboratory Procedure Result Units Ref Interval Accession Collected Received Thyroid Peroxidase (TPO) Antibody 5.0 IU/mL [0.0-9.0] 18-289-900139 16-Oct-18 Complement Component 3 50 mg/dl 18-289-900139

More information

Autoantibodies in the Idiopathic Inflammatory Myopathies

Autoantibodies in the Idiopathic Inflammatory Myopathies Autoantibodies in the Idiopathic Inflammatory Myopathies Steven R. Ytterberg, M.D. Division of Rheumatology Mayo Clinic Rochester, MN The Myositis Association Annual Conference St. Louis, MO Sept. 25,

More information

Four Types of Vertebrate Tissue

Four Types of Vertebrate Tissue BIO 121 Molecular Cell Biology Lecture Section IV A. Cells in the Context of Tissue, Organ and Organismal Architecture B. Wound Healing Four Types of Vertebrate Tissue 1.Epithelium 2.Connective Tissue

More information

Requirements in the Development of an Autoimmune Disease Amino Acids in the Shared Epitope

Requirements in the Development of an Autoimmune Disease Amino Acids in the Shared Epitope + T cell MHC/self-peptide MHC/Vβ Induction of + T H 1 mediated autoimmunity: A paradigm for the pathogenesis of rheumatoid arthritis, multiple sclerosis and type I diabetes APC Activated autoreactive +

More information

Is it Autoimmune or NOT! Presented to AONP! October 2015!

Is it Autoimmune or NOT! Presented to AONP! October 2015! Is it Autoimmune or NOT! Presented to AONP! October 2015! Four main jobs of immune system Detects Contains and eliminates Self regulates Protects Innate Immune System! Epithelial cells, phagocytic cells

More information

Nottingham Patterns of liver fibrosis and their clinical significance

Nottingham Patterns of liver fibrosis and their clinical significance Nottingham 2006 Patterns of liver fibrosis and their clinical significance Alastair D Burt Professor of Pathology and Dean of Clinical Medicine University of Newcastle upon Tyne Collapse of reticulin

More information

Connective Tissue Response in IBD

Connective Tissue Response in IBD Connective Tissue Response in IBD Dr I C Lawrance MB BS, PhD FRACP School of Medicine and Pharmacology, University of Western Australia, Fremantle Hospital Intestinal response to Chronic Inflammation Control

More information

Myositis and Your Lungs

Myositis and Your Lungs Myositis and Your Lungs 2013 TMA Annual Patient Meeting Louisville, Kentucky Chester V. Oddis, MD University of Pittsburgh Director, Myositis Center Myositis Heterogeneous group of autoimmune syndromes

More information

DIA Oligonucleotide-Based Therapeutics Conference

DIA Oligonucleotide-Based Therapeutics Conference DIA Oligonucleotide-Based Therapeutics Conference North Bethesda MD October 25-27 Translating PD Biomarkers From Preclinical Studies to Clinical Trials: MRG-201, an Oligonucleotide Mimic of mir- 29, Inhibits

More information

CTD-related Lung Disease

CTD-related Lung Disease 13 th Cambridge Chest Meeting King s College, Cambridge April 2015 Imaging of CTD-related Lung Disease Dr Sujal R Desai King s College Hospital, London Disclosure Statement No Disclosures / Conflicts of

More information

WHAT THE EXPERIMENTAL MODELS CAN TEACH US IN NAFLD/NASH? Claudio Tiribelli, MD PhD Scientific Director FIF

WHAT THE EXPERIMENTAL MODELS CAN TEACH US IN NAFLD/NASH? Claudio Tiribelli, MD PhD Scientific Director FIF WHAT THE EXPERIMENTAL MODELS CAN TEACH US IN NAFLD/NASH? Claudio Tiribelli, MD PhD Scientific Director FIF ctliver@fegato.it Worldwide estimated prevalence of NAFLD distribution of PNPLA3 genotypes 2017-Younussi

More information

Disclosures. Clinical Approach: Evaluating CTD-ILD for the pulmonologist. ILD in CTD. connective tissue disease or collagen vascular disease

Disclosures. Clinical Approach: Evaluating CTD-ILD for the pulmonologist. ILD in CTD. connective tissue disease or collagen vascular disease Disclosures Clinical Approach: Evaluating CTD-ILD for the pulmonologist Industry relationships: Actelion, atyr Pharma, Boehringer-Ingelheim, Genentech- Roche, Gilead Aryeh Fischer, MD Associate Professor

More information

Role of Inflammatory and Progenitor Cells in Pulmonary Vascular Remodeling: Potential Role for Targeted Therapies. Traditional Hypothesis Stress

Role of Inflammatory and Progenitor Cells in Pulmonary Vascular Remodeling: Potential Role for Targeted Therapies. Traditional Hypothesis Stress 3/1/212 Role of Inflammatory and Progenitor Cells in Pulmonary Vascular Remodeling: Potential Role for Targeted Therapies K.R. Stenmark University of Colorado Denver, CO 845 Prominent Fibroproliferative

More information

Scleroderma FAQ. About this Document

Scleroderma FAQ. About this Document Scleroderma FAQ About this Document The Scleroderma FAQ * is a comprehensive document that covers systemic scleroderma diagnosis and treatment. All information contained in the FAQ is based on current

More information

INTERPRETATION OF LABORATORY TESTS IN RHEUMATIC DISEASE

INTERPRETATION OF LABORATORY TESTS IN RHEUMATIC DISEASE INTERPRETATION OF LABORATORY TESTS IN RHEUMATIC DISEASE Laboratory tests are an important adjunct in the clinical diagnosis of rheumatic diseases and are sometimes helpful in monitoring the activity of

More information

What will we discuss today?

What will we discuss today? Autoimmune diseases What will we discuss today? Introduction to autoimmune diseases Some examples Introduction to autoimmune diseases Chronic Sometimes relapsing Progressive damage Epitope spreading more

More information

Tools to Aid in the Accurate Diagnosis of. Connective Tissue Disease

Tools to Aid in the Accurate Diagnosis of. Connective Tissue Disease Connective Tissue Disease Tools to Aid in the Accurate Diagnosis of Connective Tissue Disease Connective Tissue Disease High quality assays and novel tests Inova offers a complete array of assay methods,

More information

Thomas A. Medsger, Jr., MD University of Pittsburgh School of Medicine. Disclosures: None

Thomas A. Medsger, Jr., MD University of Pittsburgh School of Medicine. Disclosures: None Thomas A. Medsger, Jr., MD University of Pittsburgh School of Medicine Disclosures: None 4000+ patients enrolled 1972- present; 5+ visits per patient; 20,000+ patient years of follow- up All clinical and

More information

Peripheral (digital) vasculopathy in systemic. sclerosis. Ariane Herrick

Peripheral (digital) vasculopathy in systemic. sclerosis. Ariane Herrick Peripheral (digital) vasculopathy in systemic sclerosis Ariane Herrick Raynaud s phenomenon VASOPASM DEOXYGENATION REPERFUSION Main causes of RP Primary (idiopathic) Connective tissue diseases, including

More information

University of Pretoria

University of Pretoria University of Pretoria Serodiagnostic Procedures Performed in the Department of Immunology Dr Pieter WA Meyer 1.Autoimmune Diseases Automated Anti-nuclear antibodies Anti-gliadin/ tissue transglutaminase

More information

Disclosures. Scleroderma: Early Diagnosis How early is early? 10/28/2013. Difficult Scleroderma: How do I Approach this Patient?

Disclosures. Scleroderma: Early Diagnosis How early is early? 10/28/2013. Difficult Scleroderma: How do I Approach this Patient? Disclosures Financial support: None Difficult Scleroderma: How do I Approach this Patient? Francesco Boin, MD Assistant Professor of Medicine Director, Translational Research Johns Hopkins Scleroderma

More information

RHEUMATOLOGY OVERVIEW. Carmelita J. Colbert, MD Assistant Professor of Medicine Division of Rheumatology Loyola University Medical Center

RHEUMATOLOGY OVERVIEW. Carmelita J. Colbert, MD Assistant Professor of Medicine Division of Rheumatology Loyola University Medical Center RHEUMATOLOGY OVERVIEW Carmelita J. Colbert, MD Assistant Professor of Medicine Division of Rheumatology Loyola University Medical Center What is Rheumatology? Medical science devoted to the rheumatic diseases

More information

DocSpot what patients want to know

DocSpot what patients want to know DocSpot what patients want to know Professor Chris Denton Royal Free Hospital London, UK Madrid, February 2012 Copyright 2011 Raynaud's & Scleroderma Association. Charity Reg. No. 326306 DocSpot Live!

More information

Neoplasia 18 lecture 8. Dr Heyam Awad MD, FRCPath

Neoplasia 18 lecture 8. Dr Heyam Awad MD, FRCPath Neoplasia 18 lecture 8 Dr Heyam Awad MD, FRCPath ILOS 1. understand the angiogenic switch in tumors and factors that stimulate and inhibit angiogenesis. 2. list the steps important for tumor metastasis

More information

The biological bases of treatment related cardiac and lung toxicity

The biological bases of treatment related cardiac and lung toxicity The biological bases of treatment related cardiac and lung toxicity Monica Mangoni Cardiopulmonary toxicity of anticancer treatments Chemotherapy TKIs MoAB CARDIAC TOXICITY Radiation effect -------------------------------Early

More information

Cancer Biology Course. Invasion and Metastasis

Cancer Biology Course. Invasion and Metastasis Cancer Biology Course Invasion and Metastasis 2016 Lu-Hai Wang NHRI Cancer metastasis Major problem: main reason for killing cancer patients, without it cancer can be cured or controlled. Challenging questions:

More information

Ανάπτυξη Βιοτράπεζας για την Ανίχνευση Πρώιμων Βιοδεικτών σε Ασθενείς με Χρόνια Νεφρική Νόσο

Ανάπτυξη Βιοτράπεζας για την Ανίχνευση Πρώιμων Βιοδεικτών σε Ασθενείς με Χρόνια Νεφρική Νόσο Ανάπτυξη Βιοτράπεζας για την Ανίχνευση Πρώιμων Βιοδεικτών σε Ασθενείς με Χρόνια Νεφρική Νόσο ΔΗΜΗΤΡΙΟΣ Σ. ΓΟΥΜΕΝΟΣ Νεφρολογικό και Μεταμοσχευτικό Κέντρο Πανεπιστημιακό Νοσοκομείο Πατρών Causes of chronic

More information

SCLERODERMA: An Update. What You Need To Know

SCLERODERMA: An Update. What You Need To Know SCLERODERMA: An Update What You Need To Know Pre Test Question #1 The onset of systemic sclerosis is typically: A. In the 1st decade of life B. Between the 4th and 6th decade C. Equal in all age groups

More information

Supporting Information

Supporting Information Supporting Information Rock et al. 10.1073/pnas.1117988108 Fig. S1. Heterogeneity of stromal cells in normal and fibrotic mouse lungs. Sections of normal mouse lungs (A and D) and fibrotic lungs collected

More information

This month, we are very pleased to introduce some new tests for Scleroderma as well as some test changes to our existing scleroderma tests/panels.

This month, we are very pleased to introduce some new tests for Scleroderma as well as some test changes to our existing scleroderma tests/panels. February 20, 2017 Client Letter Test Update February 2017 Dear Colleague: This month, we are very pleased to introduce some new tests for Scleroderma as well as some test changes to our existing scleroderma

More information

General Features. Originates mostly from mesoderm. Composed of cells, fibres and extracellular matrix. Highly vascular. Variable regenerative power.

General Features. Originates mostly from mesoderm. Composed of cells, fibres and extracellular matrix. Highly vascular. Variable regenerative power. Connective Tissue General Features Originates mostly from mesoderm. Composed of cells, fibres and extracellular matrix. Highly vascular. Variable regenerative power. Functions of Connective Tissue Support:

More information

Glomerular Pathology- 1 Nephrotic Syndrome. Dr. Nisreen Abu Shahin

Glomerular Pathology- 1 Nephrotic Syndrome. Dr. Nisreen Abu Shahin Glomerular Pathology- 1 Nephrotic Syndrome Dr. Nisreen Abu Shahin The Nephrotic Syndrome a clinical complex resulting from glomerular disease & includes the following: (1) massive proteinuria (3.5 gm /day

More information

Jeopardy. What s the rash? $100 $100 $100 $100 $100 $200 $200 $200 $200 $200 $300 $300 $300 $300 $300 $400 $400 $400 $400 $400

Jeopardy. What s the rash? $100 $100 $100 $100 $100 $200 $200 $200 $200 $200 $300 $300 $300 $300 $300 $400 $400 $400 $400 $400 Jeopardy Antibodies & more antibodies Aching joints What s the rash? Potpourri Image Challenge $100 $100 $100 $100 $100 $200 $200 $200 $200 $200 $300 $300 $300 $300 $300 $400 $400 $400 $400 $400 $500 $500

More information

Postn MCM Smad2 fl/fl Postn MCM Smad3 fl/fl Postn MCM Smad2/3 fl/fl. Postn MCM. Tgfbr1/2 fl/fl TAC

Postn MCM Smad2 fl/fl Postn MCM Smad3 fl/fl Postn MCM Smad2/3 fl/fl. Postn MCM. Tgfbr1/2 fl/fl TAC A Smad2 fl/fl Smad3 fl/fl Smad2/3 fl/fl Tgfbr1/2 fl/fl 1. mm B Tcf21 MCM Tcf21 MCM Smad3 fl/fl Tcf21 MCM Smad2/3 fl/fl Tcf21 MCM Tgfbr1/2 fl/fl αmhc MCM C 1. mm 1. mm D Smad2 fl/fl Smad3 fl/fl Smad2/3

More information

Growth Factors. BIT 230 Walsh Chapter 7

Growth Factors. BIT 230 Walsh Chapter 7 Growth Factors BIT 230 Walsh Chapter 7 3 Definitions Autocrine: a mode of hormone action in which a hormone affects the function of the cell type that produced it. Paracrine: Relating to the release of

More information

T Cell Effector Mechanisms I: B cell Help & DTH

T Cell Effector Mechanisms I: B cell Help & DTH T Cell Effector Mechanisms I: B cell Help & DTH Ned Braunstein, MD The Major T Cell Subsets p56 lck + T cells γ δ ε ζ ζ p56 lck CD8+ T cells γ δ ε ζ ζ Cα Cβ Vα Vβ CD3 CD8 Cα Cβ Vα Vβ CD3 MHC II peptide

More information

Systemic sclerosis and GI involvement

Systemic sclerosis and GI involvement Systemic sclerosis and GI involvement Dr Maggie Larché, MRCP(UK), PhD Associate Professor, Division of Rheumatology, McMaster University St Joseph s Hospital Scleroderma CME, St Joseph s Hospital, September

More information

MEK/ERK INHIBITORS: A PROOF-OF-CONCEPT STUDY IN LUNG FIBROSIS

MEK/ERK INHIBITORS: A PROOF-OF-CONCEPT STUDY IN LUNG FIBROSIS MEK/ERK INHIBITORS: A PROOF-OF-CONCEPT STUDY IN LUNG FIBROSIS Andrew Leask Departments of Dentistry and Physiology and Pharmacology University of Western Ontario Dental Sciences Building London ON Canada

More information

MOLECULAR IMMUNOLOGY Manipulation of immune response Autoimmune diseases & the pathogenic mechanism

MOLECULAR IMMUNOLOGY Manipulation of immune response Autoimmune diseases & the pathogenic mechanism MOLECULAR IMMUNOLOGY Manipulation of immune response Autoimmune diseases & the pathogenic mechanism SCHMAIEL SHIRDEL CONTENT 2 Introduction Autoimmune diseases Classification Involved components Autoimmune

More information

Animal Tissue Culture SQG 3242 Biology of Cultured Cells. Dr. Siti Pauliena Mohd Bohari

Animal Tissue Culture SQG 3242 Biology of Cultured Cells. Dr. Siti Pauliena Mohd Bohari Animal Tissue Culture SQG 3242 Biology of Cultured Cells Dr. Siti Pauliena Mohd Bohari The Culture Environment Changes of Cell s microenvironment needed that favor the spreading, migration, and proliferation

More information

Tolerance, autoimmunity and the pathogenesis of immunemediated inflammatory diseases. Abul K. Abbas UCSF

Tolerance, autoimmunity and the pathogenesis of immunemediated inflammatory diseases. Abul K. Abbas UCSF Tolerance, autoimmunity and the pathogenesis of immunemediated inflammatory diseases Abul K. Abbas UCSF Balancing lymphocyte activation and control Activation Effector T cells Tolerance Regulatory T cells

More information

Most abundant and widely distributed tissues in the body Binds, support, and strengthen body tissues, protect and insulate internal organ, serve as

Most abundant and widely distributed tissues in the body Binds, support, and strengthen body tissues, protect and insulate internal organ, serve as Connective tissue Most abundant and widely distributed tissues in the body Binds, support, and strengthen body tissues, protect and insulate internal organ, serve as major transport system, compartmentalizes

More information

Autoantibodies panel ANA

Autoantibodies panel ANA Autoantibodies panel ANA Anti-nuclear antibodies, ANA screening General: Anti-nuclear antibodies (ANA) contain all kinds of autoantibodies against nuclear antigens. Their targets are cell components in

More information

Overview of glomerular diseases

Overview of glomerular diseases Overview of glomerular diseases *Endothelial cells are fenestrated each fenestra: 70-100nm in diameter Contractile, capable of proliferation, makes ECM & releases mediators *Glomerular basement membrane

More information

What' t s ' t h t e e m ain i r o r le l e o f c onnec e ti t v i e v t s i sue?

What' t s ' t h t e e m ain i r o r le l e o f c onnec e ti t v i e v t s i sue? connective tissue Dr. Zahiri What's the main role of connective tissue? o Mechanical support o Material that connects and binds cells into tissues o Binds tissues to each other o Protection and Defense

More information

What is Autoimmunity?

What is Autoimmunity? Autoimmunity What is Autoimmunity? Robert Beatty MCB150 Autoimmunity is an immune response to self antigens that results in disease. The immune response to self is a result of a breakdown in immune tolerance.

More information

What is Autoimmunity?

What is Autoimmunity? Autoimmunity What is Autoimmunity? Robert Beatty MCB150 Autoimmunity is an immune response to self antigens that results in disease. The immune response to self is a result of a breakdown in immune tolerance.

More information

Tumor microenvironment Interactions and Lung Cancer Invasiveness. Pulmonary Grand Rounds Philippe Montgrain, M.D.

Tumor microenvironment Interactions and Lung Cancer Invasiveness. Pulmonary Grand Rounds Philippe Montgrain, M.D. Tumor microenvironment Interactions and Lung Cancer Invasiveness Pulmonary Grand Rounds Philippe Montgrain, M.D. February 26, 2009 Objectives Review epithelial mesenchymal transition (EMT), and its implications

More information

renoprotection therapy goals 208, 209

renoprotection therapy goals 208, 209 Subject Index Aldosterone, plasminogen activator inhibitor-1 induction 163, 164, 168 Aminopeptidases angiotensin II processing 64 66, 214 diabetic expression 214, 215 Angiotensin I intrarenal compartmentalization

More information

Self-tolerance. Lack of immune responsiveness to an individual s own tissue antigens. Central Tolerance. Peripheral tolerance

Self-tolerance. Lack of immune responsiveness to an individual s own tissue antigens. Central Tolerance. Peripheral tolerance Autoimmunity Self-tolerance Lack of immune responsiveness to an individual s own tissue antigens Central Tolerance Peripheral tolerance Factors Regulating Immune Response Antigen availability Properties

More information

Cell Polarity and Cancer

Cell Polarity and Cancer Cell Polarity and Cancer Pr Jean-Paul Borg Email: jean-paul.borg@inserm.fr Features of malignant cells Steps in Malignant Progression Cell polarity, cell adhesion, morphogenesis and tumorigenesis pathways

More information

Amino acid sequences in the β chain HLA- DRB*0401 molecules dictate susceptibility to RA Amino Acids in the Shared Epitope

Amino acid sequences in the β chain HLA- DRB*0401 molecules dictate susceptibility to RA Amino Acids in the Shared Epitope MHC/self-peptide MHC/Vβ TCR Vβx + Vβx T cell Induction of + TH1 mediated autoimmunity: A paradigm for the pathogenesis of rheumatoid arthritis, multiple sclerosis and APC type I diabetes TCR Vβx Activated

More information

A clinical syndrome, composed mainly of:

A clinical syndrome, composed mainly of: Nephritic syndrome We will discuss: 1)Nephritic syndrome: -Acute postinfectious (poststreptococcal) GN -IgA nephropathy -Hereditary nephritis 2)Rapidly progressive GN (RPGN) A clinical syndrome, composed

More information

Systemic sclerosis (SSC)

Systemic sclerosis (SSC) Systemic sclerosis (SSC) -Is a multi system autoimmune disease, characterized by fibrosis of the skin and variable pattern of other visceral -SSC: Is a relatively UN common disease -Prevalence in U S A

More information

Regenerative Medicine for Sclerotic Disorders

Regenerative Medicine for Sclerotic Disorders Regenerative Medicine Regenerative Medicine for Sclerotic Disorders JMAJ 7(7): 3 37, Toshikazu NAKAMURA rofessor, Division of Molecular Regenerative Medicine, Course of Advanced Medicine, Osaka University

More information

Assays. New. New. Combinations. Possibilities. Patents: EP , AU

Assays. New. New. Combinations. Possibilities. Patents: EP , AU Assays Patents: EP 2362222, AU 2011217190 New Combinations New Possibilities Technology Classical Handling of Autoimmune Diagnostics 2-Step Diagnostics 1 st Screening 2 nd Confirmation Cell based IFA ELISA

More information

Obstructive nephropathy: Insights from genetically engineered animals

Obstructive nephropathy: Insights from genetically engineered animals Kidney International, Vol. 68 (2005), pp. 925 937 Obstructive nephropathy: Insights from genetically engineered animals JEAN-LOUP BASCANDS and JOOST P. SCHANSTRA Inserm U388, Institut Louis Bugnard, Touluse

More information

Dr Mahmood S Choudhery, PhD, Postdoc (USA) Assistant Professor Tissue Engineering and Regenerative Medicine King Edward Medical University/Mayo

Dr Mahmood S Choudhery, PhD, Postdoc (USA) Assistant Professor Tissue Engineering and Regenerative Medicine King Edward Medical University/Mayo Integration of Cells into Tissues Dr Mahmood S Choudhery, PhD, Postdoc (USA) Assistant Professor Tissue Engineering and Regenerative Medicine King Edward Medical University/Mayo Hospital Lahore 1. How

More information

Histology = the study of tissues. Tissue = a complex of cells that have a common function

Histology = the study of tissues. Tissue = a complex of cells that have a common function { EPITHELIAL TISSUE Histology = the study of tissues Tissue = a complex of cells that have a common function The Four Primary Tissue Types: Epithelium (epithelial tissue) covers body surfaces, lines body

More information

Contents. Welcome Address... iii EULAR 2017 Abstracts Reviewers... iv. Speakers Abstracts

Contents. Welcome Address... iii EULAR 2017 Abstracts Reviewers... iv. Speakers Abstracts vi Welcome Address... iii EULAR 2017 Abstracts Reviewers... iv Speaker Presentations Speakers Abstracts Wednesday, 14 June 2017 SP0001 SP0004 Joint EULAR - APLAR session: novel animal models - where no

More information

2/23/18. Disclosures. Rheumatic Diseases of Childhood. Making Room for Rheumatology. I have nothing to disclose. James J.

2/23/18. Disclosures. Rheumatic Diseases of Childhood. Making Room for Rheumatology. I have nothing to disclose. James J. Making Room for Rheumatology James J. Nocton, MD Disclosures I have nothing to disclose Rheumatic Diseases of Childhood Juvenile Idiopathic Arthritis (JIA) Systemic Lupus Erythematosus (SLE) Juvenile Dermatomyositis

More information

CHAPTER VII CONCLUDING REMARKS AND FUTURE DIRECTION. Androgen deprivation therapy is the most used treatment of de novo or recurrent

CHAPTER VII CONCLUDING REMARKS AND FUTURE DIRECTION. Androgen deprivation therapy is the most used treatment of de novo or recurrent CHAPTER VII CONCLUDING REMARKS AND FUTURE DIRECTION Stathmin in Prostate Cancer Development and Progression Androgen deprivation therapy is the most used treatment of de novo or recurrent metastatic PCa.

More information